Alzheimer’s

Drug development possibilities for brain diseases linked to tau protein.

Model tested on tens of thousands of routine brain scans spotted disease risk with 90% accuracy.

It highlights the knowledge gap needed to reduce cognitive decline.

Obesity-related neurodegeneration mimics Alzheimer’s disease.

The study supports the idea that components in the human blood can modulate the formation of new brain cells.

Blood-based markers may reveal Alzheimer's disease ten years before symptoms show.

This treatment option is the latest therapy to target.

A clue to the molecular cause of Alzheimer’s.

A modified immune protein harming brain connections is much more common in the brains of women with Alzheimer’s.

If we can find these individuals early enough, we’ll have a better chance of seeing if the drugs are effective.

The discovery provides a new therapeutic target to prevent the onset of neurodegenerative diseases.

Separating densely packed molecules before imaging makes them visible for the first time.